ID   SB.06
AC   CVCL_VJ93
SY   SB_06
DR   cancercelllines; CVCL_VJ93
DR   Cosmic; 2498852
DR   Wikidata; Q98129336
RX   PubMed=26962861;
CC   Doubling time: 45.9 hours (PubMed=26962861).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=26962861).
CC   Sequence variation: Mutation; HGNC; HGNC:9099; PLXNA1; Simple; p.Asp863Asn (c.2587G>A); dbSNP=rs367569800; Zygosity=Unspecified (PubMed=26962861).
CC   Omics: Genomics; Whole genome sequencing.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 10-04-25; Version: 7
//
RX   PubMed=26962861; DOI=10.1371/journal.pone.0149833; PMCID=PMC4786220;
RA   Sorber R., Teper Y., Abisoye-Ogunniyan A., Waterfall J.J., Davis S.,
RA   Killian J.K., Pineda M.A., Ray S., McCord M.R., Pflicke H.,
RA   Burkett S.S., Meltzer P.S., Rudloff U.;
RT   "Whole genome sequencing of newly established pancreatic cancer lines
RT   identifies novel somatic mutation (c.2587G>A) in axon guidance
RT   receptor plexin A1 as enhancer of proliferation and invasion.";
RL   PLoS ONE 11:e0149833.1-e0149833.25(2016).
//